Strs Ohio Trims Stake in Becton, Dickinson and Company $BDX

Strs Ohio cut its stake in Becton, Dickinson and Company (NYSE:BDX) by 4.9% in the first quarter, HoldingsChannel reports. The fund owned 288,041 shares of the medical instruments supplier’s stock after selling 14,778 shares during the period. Strs Ohio’s holdings in Becton, Dickinson and Company were worth $45,289,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in BDX. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. Graybill Wealth Management LTD. grew its position in shares of Becton, Dickinson and Company by 47.3% during the 3rd quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock valued at $5,164,000 after acquiring an additional 8,859 shares during the period. Danske Bank A S purchased a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $34,596,000. Cinctive Capital Management LP raised its holdings in Becton, Dickinson and Company by 71.6% in the 3rd quarter. Cinctive Capital Management LP now owns 16,847 shares of the medical instruments supplier’s stock worth $3,153,000 after purchasing an additional 7,028 shares during the period. Finally, Legal & General Group Plc raised its holdings in Becton, Dickinson and Company by 3.9% in the 3rd quarter. Legal & General Group Plc now owns 1,919,404 shares of the medical instruments supplier’s stock worth $359,255,000 after purchasing an additional 71,676 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on BDX. Wells Fargo & Company raised their price objective on Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. The Goldman Sachs Group dropped their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Royal Bank Of Canada set a $175.00 price target on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Finally, Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus target price of $181.00.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 5,188 shares of company stock worth $765,120. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $158.10 on Friday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The stock has a 50 day moving average of $147.94 and a two-hundred day moving average of $169.41. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market cap of $43.56 billion, a P/E ratio of 40.02, a price-to-earnings-growth ratio of 10.82 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, analysts expect that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were issued a $1.05 dividend. The ex-dividend date was Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.